Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its pipeline ahead of a key patent expiry, as US hedge fund Citadel took the largest short position ...

在一众欧洲大型制药股中，葛兰素史克(GSK.US)长期表现不佳。随着关键药物专利即将到期和疫苗销量下降，一些市场参与者表示，这家制药公司可能会再次吸引到激进投资者的关注， ...

A man has been arrested on suspicion of attempted murder after a van struck two people in Poulton Le-Fylde just after midnight. Police received a report at 12.50am today, Sunday, that a Ford ...

A product of this is a blood cancer breakthrough compound named Blenrep. It is among the reasons that GSK is so confident about forward prospects, lifting its long-term target for sales to £ ...

This year, GSK expects five product approvals, including the relaunch of blood cancer drug Blenrep, which it estimates could eventually reach annual sales of more than 3 billion pounds. "We are ...

At the forefront, our potential step changes in treatment with Blenrep or novel ADC treatment for multiple myeloma and depemokimab, or new long-acting IL-5 medicine for the treatment of severe asthma.

It also faces competition from Pfizer and Moderna. Still, the drugmaker is optimistic about its prospects for the potential re-launch of its blood cancer drug Blenrep this year. Following positive ...

Blenrep and depemokimab are expected to launch in 2025, with Blenrep's FDA PDUFA date set for July. Chief Financial Officer Julie Brown noted, "Core operating margin improved to 29.2%, up 130 ...

For 2025, GSK expects further growth in sales and core earnings, supported by plans to launch five medicines, including a comeback of previously withdrawn multiple myeloma treatment Blenrep.

The latest increase reflects the revival of the once-withdrawn antibody-drug conjugate Blenrep, as well as “multiple launch opportunities in the ’26-to-’31 period,” GSK CEO Emma Walmsley ...